Adolescent depression and suicide are on the rise, yet effective care is limited by long waitlists and large out-of-pocket costs for therapy, limited pharmacological options, and stigma surrounding mental health.
SparkRx is available now under the FDA’s policy to treat psychiatric disorders during COVID-19.
Limbix is creating digital therapeutics (DTx) to enable doctors to offer digital, evidence-based, therapeutic interventions for adolescent mental health.
DTx require strict compliance with FDA quality management standards and are validated through rigorous clinical trials. Typically, upon FDA clearance, DTx can be offered by a doctor to treat specific medical conditions.
Limbix creates digital therapeutics with significant input from teenagers who provide us valuable feedback. If you are a teen interested in helping Limbix design thoughtful digital experiences for current and future generations of young people, email info@limbix.com!
Learn More
Limbix relies on clinical experts who provide critical product feedback to help ensure the digital therapeutics we create are evidence-based and beneficial for patients. If you are a physician looking to connect with Limbix to provide your input, please join our Physician Advisory Group.
Join Physician Advisory Group
Digital therapeutics for adolescent mental health
